Key facts
- It has raised $24.2M; the latest was Later Stage VC in Sep 2025.
- Notable investors include Google for Startups, European Innovation Council, European Commission, Quiet Capital, London & Partners. — 35 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 35 names
- ·Watchlist + deal alerts for iLoF
- ·The full record, as it builds
Funding rounds
No funding rounds for iLoF are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About iLoF
Developer of an artificial intelligence-powered digital health platform designed to accelerate the future of personalized drug discovery and development. The company's platform uses advanced photonics to collect data to build a digital library of biomarkers and biological profiles, bringing physicists, biologists, and data scientists to study personalized treatments for patients, enabling healthcare companies to make clinical trials less expensive and patient-centric.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2019
- Employees
- 39
- Website
- ilof.tech/
- Ownership
- Privately Held (backing)
iLoF doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in iLoF shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on iLoF in its N-PORT filings yet. We sweep new filings monthly.